Full-year earnings and revenue rose 12.4% and 12%, respectively. Much of Perrigo's top line growth during the quarter was attributed to its recent acquisitions of four companies — Sergeant's Pet Care Products, pet care products maker Velcera, prescription drug maker Rosemont Pharmaceuticals and eye-care company Fera Pharmaceuticals — which generated a combined $83 million in sales during the quarter. New products contributed to $30 million in new sales, and Perrigo's base business grew by $21 million. Growth in consumer health care Perrigo Company (NYSE:PRGO)'s consumer health care unit is its largest business segment, accounting for 58% of the company's top line with $563 million in sales. Revenue at the segment — which covers a range of over-the-counter and generic medications, dietary products, and feminine hygiene products — rose 16% from the prior-year quarter.